(dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in. Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide).
|Published (Last):||20 December 2007|
|PDF File Size:||3.56 Mb|
|ePub File Size:||1.22 Mb|
|Price:||Free* [*Free Regsitration Required]|
Am J Psychiatry[E-pub ahead of print]. As such, this study fills an important gap in our knowledge. Patients were categorized into 2 groups according to whether or not dofetilide was discontinued during the index hospitalization.
Further, dofetilide is the only antiarrhythmic drug, besides amiodarone, that is approved for use in patients with severe left ventricular systolic dysfunction 15, In 6 of the 8 patients, hydrochlorothiazide was discontinued during the hospital admission for dofetilide.
The higher rate of dofetilide discontinuation in our cohort compared with other observational studies is likely from inclusion of patients who were taking other QT-prolonging drugs, which reflects the real-world experience Although it is ideal to stop or replace these medications with alternatives when starting dofetilide, it is not always possible.
Serum electrolytes, including potassium and magnesium, were monitored daily during the hospital stay and corrected as needed.
Abstract Objectives The purpose of this study was to determine the incidence and correlates of QT prolongation or ventricular tachycardia VT resulting in discontinuation of dofetilide in a real-world setting.
These results suggest that the incidence of discontinuation of dofetilide because of adverse events is much higher in a real-world setting than has been reported in clinical trials.
To our knowledge, this is the one of the few studies study assessing the incidence and predictors of discontinuation of dofetilide in a real-world, inpatient setting. In symptomatic patients with AF, antiarrhythmic therapy can be useful ;ackage achieve and maintain normal sinus rhythm to alleviate symptoms and optimize heart failure management 7— Neither study reported information on the concomitant use of QTc-prolonging drugs. dovetilide
Dofetilide (Tikosyn) | Pharmacy
Dofetilide is a class ;ackage antiarrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation. JI Intervent Cardiac Electrophysiol Background Dofetilide is a class III antiarrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation.
Patients who were taking concomitant QT-prolonging drugs were 1. In comparison to patients who were taking no other QT-prolonging medications, the odds of dofetilide discontinuation was 1. Concomitant use packge other QT-prolonging drugs was associated with discontinuation of dofetilide.
Because of a risk of QT prolongation and VT, patients starting dofetilide need to be hospitalized for 3 days to closely monitor telemetry and electrocardiography. Insret These data indicate that the incidence of dofetilide discontinuation because of QT prolongation or VT in a real-world setting is remarkably higher than that reported in clinical trials.
We’re strengthening digital security to protect you.
Conclusions The incidence of QT prolongation or VT that lead to discontinuation of dofetilide is remarkably higher in the real-world setting than in clinical trials.
In large-scale population studies, AF has been associated with adverse cardiovascular events, including thromboembolism, heart failure, sudden cardiac death, and cardiovascular mortality 4—6.
All Interactions with Dofetilide
Dofetilide dosing was based on glomerular filtration rate GFR: Two patients packaeg a normal baseline QTc developed VT after the second dose. Outcomes of Citalopram dose-risk mitigation in a veteran population.
Of these 8 patients, 1 We conducted a retrospective cohort study of consecutive patients hospitalized for starting dofetilide to treat AF at the Minneapolis Veterans Affairs Health Care System from to Br J Clin Pharmacol None of the patients had worsening of renal function during the index hospitalization.
ECG was obtained before the initiation of cofetilide and 2 h after each dose and was monitored for QT interval prolongation.
This study was approved by the institutional review board and the Research and Development Committee at our institution. Dofetilide initiation protocol Dofetilide was packagr during a h inpatient hospitalization per standard protocol However, the discontinuation rate of dofetilide is higher in cohort studies such as ours. The incidence of QT prolongation packgae VT that lead to discontinuation of dofetilide is remarkably higher in the real-world setting than in clinical trials.
The aim of this study was to evaluate the incidence and predictors of QT prolongation or VT leading to discontinuation of dofetilide in a real-world clinical setting.